| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007982993 |
| P356 | DOI | 10.1186/1471-2474-12-204 |
| P932 | PMC publication ID | 3184114 |
| P698 | PubMed publication ID | 21929807 |
| P5875 | ResearchGate publication ID | 51654117 |
| P2093 | author name string | Henry J Henk | |
| Sarika Ogale | |||
| Elena Hitraya | |||
| P2860 | cites work | Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study | Q24791246 |
| Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data | Q31011382 | ||
| Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank | Q33451953 | ||
| Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? | Q33566367 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis | Q34315535 | ||
| Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis | Q34515105 | ||
| IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial | Q34795777 | ||
| Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period | Q34896269 | ||
| Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. | Q35637221 | ||
| Joint damage and disability in rheumatoid arthritis: an updated systematic review | Q35669577 | ||
| Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy | Q36694682 | ||
| Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population | Q36763024 | ||
| Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists | Q37633537 | ||
| Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study | Q40360283 | ||
| Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D | Q43205844 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy | Q48454849 | ||
| Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. | Q51689568 | ||
| British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). | Q51853711 | ||
| British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). | Q51937590 | ||
| Health Insurance Portability and Accountability Act of 1996. Public Law 104-191. | Q53422751 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| Rheumatoid arthritis | Q56656479 | ||
| Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study | Q57751326 | ||
| BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy | Q58327969 | ||
| B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents | Q80238326 | ||
| Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register | Q80785522 | ||
| Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition | Q81216018 | ||
| Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy | Q81417881 | ||
| Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry | Q82376321 | ||
| Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations | Q83295779 | ||
| Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice | Q84309443 | ||
| The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis | Q84506737 | ||
| TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice | Q84565491 | ||
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 204 | |
| P577 | publication date | 2011-09-19 | |
| P1433 | published in | BMC Musculoskeletal Disorders | Q15751716 |
| P1476 | title | Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study | |
| P478 | volume | 12 |
| Q59797838 | Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies |
| Q28069373 | Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods |
| Q28542423 | Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study |
| Q37452967 | Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study |
| Q36942952 | Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic |
| Q36942874 | Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic |
| Q34211985 | Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population |
| Q31167447 | Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data |
| Q93131112 | Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study |
| Q38306139 | Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies |
| Q38338700 | Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review |
| Q36099620 | Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis |
| Q36274355 | Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis |
| Q38921982 | Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry |
| Q38915704 | Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil |
| Q37167818 | Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan |
| Q92862530 | Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery |
| Q40314992 | Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. |
| Q40942139 | The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. |
| Q38034134 | Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings |
| Q37184062 | Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis |
| Q37186231 | Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases |
Search more.